CD133+ mRNA transcripts were expressed at levels 15–30 times higher in the latter group, suggesting that CD133 transcripts strongly and negatively correlated with the clinical outcome, and were thus a potential predictor of poor prognosis in high-risk melanoma (p<0.04). This evidence concerns the gene PROM1 and melanoma.